Biotage AB (publ)

Stockholm Stock Exchange BIOT.ST

Biotage AB (publ) Total Non-Current Liabilities for the year ending December 31, 2023: USD 56.16 M

Biotage AB (publ) Total Non-Current Liabilities is USD 56.16 M for the year ending December 31, 2023, a 106.34% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Biotage AB (publ) Total Non-Current Liabilities for the year ending December 31, 2022 was USD 27.22 M, a -19.48% change year over year.
  • Biotage AB (publ) Total Non-Current Liabilities for the year ending December 31, 2021 was USD 33.80 M, a 22.84% change year over year.
  • Biotage AB (publ) Total Non-Current Liabilities for the year ending December 31, 2020 was USD 27.52 M, a 4.32% change year over year.
  • Biotage AB (publ) Total Non-Current Liabilities for the year ending December 31, 2019 was USD 26.38 M, a 83.72% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
Stockholm Stock Exchange: BIOT.ST

Biotage AB (publ)

CEO Mr. Frederic Vanderhaegen
IPO Date June 30, 2000
Location Sweden
Headquarters Box 8
Employees 675
Sector Health Care
Industries
Description

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories. It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.

Similar companies

ALIF-B.ST

AddLife AB (publ)

USD 12.08

1.50%

VITR.ST

Vitrolife AB (publ)

USD 18.25

2.79%

SECT-B.ST

Sectra AB (publ)

USD 22.17

-0.20%

CEVI.ST

CellaVision AB (publ)

USD 18.76

3.89%

BIOG-B.ST

BioGaia AB (publ)

USD 9.75

-0.95%

StockViz Staff

January 15, 2025

Any question? Send us an email